Viking Therapeutics, Inc. (VKTX)

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Viking Therapeutics (VKTX +2.82%) is one of the hopefuls in a very exciting pharmaceutical and biotech space right now: the weight loss drug market. Today, pharma giants Eli Lilly and Novo Nordisk dominate this area with their drugs, but demand is so high that there is room for a newcomer or ...

Viking Therapeutics recently initiated a Phase 1 single ascending dose trial of VK3019, a dual amylin and calcitonin receptor agonist for obesity, following US FDA clearance of its IND and adding to its expanding metabolic disease pipeline. This move, alongside ongoing late-stage development ...